Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

鈥� An ASCO Reading Room selection

February 12, 2024

Naveen S. Vasudev, MD, PhD, Gemma Ainsworth, MSc, Sarah Brown, PhD, Lisa Pickering, MD, Tom Waddell, MD, Kate Fife, MD, Richard Griffiths, MD, Anand Sharma, MD, Eszter Katona, MA, Helen Howard, PhD, Galina Velikova, MD, Anthony Maraveyas, MD, Janet Brown, MD, Carmel Pezaro, MD, Mark Tuthill, MD, Ekaterini Boleti, MD, Amit Bahl, MD, Bernadett Szabados, MD, Rosamonde E. Banks, PhD, Joanne Brown, BSc, Balaji Venugopal, MD, Poulam Patel, MD, Ankit Jain, MD, Stefan N. Symeonides, MD, Paul Nathan, MD, Fiona J. Collinson, MD, and Thomas Powles, MD

Journal of Clinical Oncology

This Reading Room is a collaboration between 麻豆传媒庐 and:

Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

Purpose

Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile.

Methods

Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the proportion of patients with a grade 3-5 treatment-related adverse event (trAE) among those who received at least one dose of therapy. The key secondary end point was 12-month progression-free survival (PFS) in the modified arm compared with historical sunitinib control. The study was not designed to formally compare arms for efficacy.

Results

Between March 2018 and January 2020, 192 patients (69.8% intermediate/poor-risk) were randomly assigned and received at least one dose of study drug. The incidence of grade 3-5 trAEs was significantly lower among participants receiving modified versus standard IPI (32.8% vs 53.1%, odds ratio 0.43 [90% CI 0.25-0.72], P=0.0075). The 12-month PFS (90% CI) using modified IPI was 46.1% (38.6-53.2). At a median follow-up of 21 months, the overall response rate was 45.3% versus 35.9% and the median PFS was 10.8 months versus 9.8 months in the modified and standard IPI groups, respectively.

Conclusion

Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.

Read an interview about the study here and expert commentary about it here.

Read the full article

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

Primary Source

Journal of Clinical Oncology

Source Reference:

麻豆传媒